(RTTNews) - Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, has entered into a definitive agreement with Gilead Sciences, Inc. (GILD) for the acquisition of its ...
Pharmaceutical Technology on MSN
Gilead Sciences to acquire Repare’s RP-3467
Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.
Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an ...
Peribacteroid membrane vesicles from pea (Pisum sativum) root nodules were isolated from membrane-enclosed bacteroids by an osmotic shock. The ATPase activity associated with this membrane preparation ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first ...
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration Repare Therapeutics Inc. (“Repare” or the “Company”) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback